Rheumatology Book

http://www.fpnotebook.com/

Rituximab

Advertisement

  1. Indications
    1. Refractory Rheumatoid Arthritis
    2. Non-Hodgkin's Lymphoma
    3. ANCA Vasculitis
  2. Contraindications
    1. Do not use with live virus vaccines
  3. Mechanism
    1. Monoclonal Antibody to the CD20 antigen that depletes CD20 positive B Cells
  4. Dosing
    1. Rheumatoid Arthritis: 1 gram IV every 2 weeks for 2 doses
      1. Administered with Methylprednisolone 100 mg
    2. Non-Hodgkin's Lymphoma or ANCA Vasculitis: 375 mg/m2 IV weekly for 4 doses
  5. Adverse Effects
    1. Severe infusion reactions (follows first infusion within 30-120 minutes)
    2. Tumor Lysis Syndrome
    3. Hepatitis B reactivation
    4. Renal insufficiency
  6. Monitoring
    1. PPD before initiating therapy
    2. Complete Blood Count at initiation of therapy and then periodically after

rituximab (C0393022)

Definition (NCI)A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.
Definition (PDQ)A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42613&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42613&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1702" NCI Thesaurus)
Definition (NCI)A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
ConceptsAmino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121) , Immunologic Factor (T129)
MSHC092560
Englishanti-CD20 monoclonal antibody, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, monoclonal antibody anti-CD20, rituximab, RITUXIMAB PREPARATION
Spanishrituximab
Parent ConceptsMonoclonal Antibodies (C0003250), Other antineoplastic drugs (C0356919), Unclassified Ingredients (C1372954), Antineoplastic Agents (C0003392), Immunosuppressive Agents (C0021081), Monoclonal antibody preparation (C1298636)
SourcesCSP, MSH, MTHSPL, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, VANDF
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree